Post by marriott on Mar 9, 2016 14:19:29 GMT
Identifying Future Exponential Growth in Biotech
Via Accesswire
March 7, 2016
LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance sheets, revenues, earnings and earnings per share. When investing in biotech throw that out the window.
In biotech, patents and intellectual property rights are like revenues and earnings in any other industry or sector, progress is measured by clinical trials and their results. With that in mind, let's look at a few biotechnology companies that are experiencing exponential growth.
Geron Corporation (GERN) has put all of its weight behind developing a single drug following its restructuring process that started in 2011. This drug is a telomerase inhibitor called imetelstat that has the potential to be a truly disease-modifying treatment for deadly blood disorders such as myelofibrosis and myelodysplastic syndrome. Despite some rough financial reports recently continues to earn investors as it fights to reward them for taking the risk.
Via Accesswire
March 7, 2016
LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance sheets, revenues, earnings and earnings per share. When investing in biotech throw that out the window.
In biotech, patents and intellectual property rights are like revenues and earnings in any other industry or sector, progress is measured by clinical trials and their results. With that in mind, let's look at a few biotechnology companies that are experiencing exponential growth.
Geron Corporation (GERN) has put all of its weight behind developing a single drug following its restructuring process that started in 2011. This drug is a telomerase inhibitor called imetelstat that has the potential to be a truly disease-modifying treatment for deadly blood disorders such as myelofibrosis and myelodysplastic syndrome. Despite some rough financial reports recently continues to earn investors as it fights to reward them for taking the risk.